Mumbai, July 24 -- The US FDA had conducted an inspection at the company's aforementioned unit from 9 June to 13 June 2025.

Post the inspection, the company received one observation in Form-483, which was classified as 'voluntary action indicated (VAI)'.

In a regulatory filing made during market hours today, Natco Pharma announced that it has received an establishment inspection report (EIR) for its API facility located in Mekaguda.

NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.

The company's consolidated net profit increased 5.3% to Rs 406.60 crore on a 14.3% jump in ...